
Alimera Sciences ALIM
Quartalsbericht 2024-Q2
hinzugefügt 07.08.2024
Alimera Sciences Zahlungsmittel 2011-2025 | ALIM
Zahlungsmittel Jährlich Alimera Sciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.1 M | 5.27 M | 16.5 M | 11.2 M | 9.43 M | 13 M | 24.1 M | 31 M | 31.1 M | 76.7 M | 12.6 M | 49.6 M | 33.1 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 76.7 M | 5.27 M | 25 M |
Zahlungsmittel Vierteljährlich Alimera Sciences
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.8 M | 14.3 M | 12.1 M | 18.8 M | 13.1 M | 5.27 M | 5.51 M | 7.89 M | 9.98 M | 16.5 M | 21.6 M | 24.8 M | 8.27 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 9.43 M | 9.43 M | 9.43 M | 9.43 M | 13 M | 13 M | 13 M | 13 M | 24.1 M | 24.1 M | 24.1 M | 24.1 M | 31 M | 31 M | 31 M | 31 M | 31.1 M | 31.1 M | 31.1 M | 31.1 M | 76.7 M | 76.7 M | 76.7 M | 76.7 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 49.6 M | 49.6 M | 49.6 M | 49.6 M | 33.1 M | 33.1 M | 33.1 M | 33.1 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 76.7 M | 5.27 M | 25.2 M |
Zahlungsmittel anderer Aktien in der Arzneimittelhersteller
| Name | Zahlungsmittel | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
37.2 M | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
114 M | $ 1.21 | 1.68 % | $ 130 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
8.86 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
1.08 M | - | 0.86 % | $ 117 M | ||
|
Catalent
CTLT
|
289 M | - | - | $ 11.5 B | ||
|
Agile Therapeutics
AGRX
|
2.56 M | - | 10.11 % | $ 58.2 M | ||
|
DURECT Corporation
DRRX
|
28.4 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
55.3 M | - | -39.89 % | $ 27.7 M | ||
|
Aurora Cannabis
ACB
|
138 M | $ 4.35 | -3.12 % | $ 86.3 M | ||
|
Endo International plc
ENDP
|
778 M | - | - | $ 28.9 M | ||
|
Zomedica Corp.
ZOM
|
13 M | - | -0.21 % | $ 98 M | ||
|
Evoke Pharma
EVOK
|
4.74 M | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
956 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
83.2 M | - | 2.45 % | $ 38.1 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
50.6 M | - | - | $ 55.5 M | ||
|
Emergent BioSolutions
EBS
|
112 M | $ 12.29 | -1.09 % | $ 629 M | ||
|
Athenex
ATNX
|
30.4 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
51.4 M | $ 21.57 | -0.12 % | $ 2.05 B | ||
|
Evolus
EOLS
|
87 M | $ 6.66 | -3.55 % | $ 413 M | ||
|
Harrow Health
HROW
|
74.1 M | $ 50.7 | 1.22 % | $ 1.65 B | ||
|
China Pharma Holdings
CPHI
|
600 K | $ 1.27 | -1.32 % | $ 22.2 M | ||
|
OrganiGram Holdings
OGI
|
24.6 M | $ 1.7 | -5.31 % | $ 402 M | ||
|
Neoleukin Therapeutics
NLTX
|
148 M | - | - | $ 193 M | ||
|
Organogenesis Holdings
ORGO
|
136 M | $ 5.19 | -1.71 % | $ 683 M | ||
|
Bausch Health Companies
BHC
|
947 M | $ 7.16 | -0.56 % | $ 2.61 B | ||
|
Lannett Company
LCI
|
87.9 M | - | 1.15 % | $ 7.11 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
5.37 M | $ 3.66 | 0.83 % | $ 4.54 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
18 M | $ 4.01 | -2.55 % | $ 56.4 M | ||
|
Rockwell Medical
RMTI
|
8.98 M | $ 0.8 | -7.01 % | $ 18.7 M | ||
|
Pacira BioSciences
PCRX
|
277 M | $ 26.17 | -1.3 % | $ 1.21 B | ||
|
Sundial Growers
SNDL
|
218 M | $ 1.71 | -1.16 % | $ 3.37 M | ||
|
PetIQ
PETQ
|
116 M | - | 1.64 % | $ 400 M | ||
|
Jupiter Wellness
JUPW
|
349 K | - | - | $ 33.6 M | ||
|
Veru
VERU
|
24.9 M | $ 2.22 | -7.71 % | $ 299 M | ||
|
Perrigo Company plc
PRGO
|
559 M | $ 13.94 | 0.87 % | $ 1.92 B | ||
|
ProPhase Labs
PRPH
|
9.11 M | $ 0.45 | -14.17 % | $ 7.13 M | ||
|
Radius Health
RDUS
|
112 M | - | - | $ 1.42 B | ||
|
cbdMD
YCBD
|
2.45 M | $ 1.43 | -15.88 % | $ 6.17 M | ||
|
Recro Pharma
REPH
|
8.1 M | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
4.09 M | $ 4.43 | -1.77 % | $ 133 M | ||
|
OptiNose
OPTN
|
73.7 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
73.4 M | $ 9.56 | -3.82 % | $ 679 M | ||
|
PLx Pharma
PLXP
|
69.4 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
80.2 M | $ 5.63 | -3.68 % | $ 230 M | ||
|
SCYNEXIS
SCYX
|
34 M | $ 0.63 | 6.75 % | $ 30.1 M | ||
|
Tricida
TCDA
|
21.1 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
207 M | $ 9.32 | -2.87 % | $ 5.76 B | ||
|
TherapeuticsMD
TXMD
|
4.33 M | $ 1.68 | -3.43 % | $ 17.5 M |